Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Hepatol. Jul 8, 2017; 9(19): 850-856
Published online Jul 8, 2017. doi: 10.4254/wjh.v9.i19.850
Table 1 Patient characteristics and outcomes
CharacteristicAll patients
Patients with first Hepascore > 0.75
All patients
Patients with first Hepascore > 0.75
NumberPercentNumberPercentmeanRangemeanRange
Number346-100-----
Gender (male)22063.67676----
SVR3811.01616----
Composite endpoint288.12121----
LRD82.388----
LD164.61212----
HCC154.31212----
Result----
Bilirubin (μmol/L)1----9.01.0-200122.3-200
GGT (U/L)1----55.08.0-100593.517-713
HA (μg/L)1----30.31.0-1211124.516-1211
A2M (μg/mL)1----2.50.6-63.61.5-6.0
Age (yr)----53.630-8058.336-80
Baseline Hepascore----0.480.02-1.00.930.77-1.0
Second Hepascore----0.570.04-1.00.870.13-1.0
Delta Hepascore----0.09-0.80-0.94-0.06-0.8-0.23
Time between baseline and second Hepascore (yr)----3.30.03-12.52.80.03-10.3
Follow-up after second Hepascore (yr)----2.20.01-7.31.90.01-5.7
Table 2 Predictors of composite clinical endpoint (liver related death, hepatocellular carcinoma, liver decompensation) using Multivariate Cox Regression
VariableFollow-up from the baseline Hepascore
Follow-up from the second Hepascore
PHazard ratio (95%CI)PHazard ratio (95%CI)
Baseline Hepascore< 0.0015.85 (2.25-15.18)0.02012.86 (1.49-111.17)
Second Hepascore--0.8913288.82 (0.0-4.6E + 53)
Delta Hepascore--0.0134.77 (1.35-16.45)
Table 3 Predictors of survival using Kaplan-Meier survival curves
TestEnd pointP value (log rank)Cohort size
Baseline Hepascore aloneComposite Endpoint< 0.001346
LRD< 0.001352
LD< 0.001348
HCC< 0.001350
Delta HepascoreComposite Endpoint0.00496
LRD0.048105
LD0.001101
HCC0.178100
Table 4 Predictors of survival Using Area under Receiver Operating Characteristic
TestEnd pointAUROC
Baseline Hepascore aloneComposite endpoint0.80
LRD0.89
LD0.75
HCC0.87
Baseline Hepascore > 0.75 and Delta HepascoreComposite endpoint0.84
LRD0.95
LD0.77
HCC0.93